Stevens-Johnson Syndrome Following Vancomycin and Linezolid: A Real-World Analysis of Post-Marketing Surveillance Data

Stevens-Johnson syndrome (SJS) has been reported as a serious adverse effect in patients treated with vancomycin or linezolid, and there is currently a lack of real-world studies comparing specific differences in adverse effects of SJS. According to the FDA's Adverse Event Reporting System (FAE...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2022-04, Vol.13, p.872854-872854
Main Authors: Ni, Ming, Yin, Xue-Dong, Hu, Wen-Juan, Zeng, Na, Zhao, Bin, Li, Zhi-Ling
Format: Article
Language:English
Subjects:
adverse event reporting system
epidemiology
linezolid
Pharmacology
SJS
vancomycin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Stevens-Johnson syndrome (SJS) has been reported as a serious adverse effect in patients treated with vancomycin or linezolid, and there is currently a lack of real-world studies comparing specific differences in adverse effects of SJS. According to the FDA's Adverse Event Reporting System (FAERS), from January 2004 to July 2021, the data of suspected SJS after the use of vancomycin and linezolid were analyzed by imbalance and Bayesian analysis. The onset time, fatality rate and hospitalization rate of vancomycin-associated SJS and linezolid-associated SJS were also investigated. 276 cases of vancomycin-related SJS reports and 63 cases of linezolid-related SJS reports were identified. These two drugs are more common in middle-aged patients (45-64 years) than other age groups, and less common in underage children (
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2022.872854